Although intraarticular gene therapy using AAV vectors has been considered a feasible treatment option for RA, and many clinical trials targeting a single cytokine such as IL-6 and TNF-α have been conducted [46, 47], the clinical benefits remain limited. The gene discussed is IL6; the disease is rheumatoid arthritis.